Last reviewed · How we verify
Midazolam 1 milligram Prefilled Syringe
Midazolam 1 milligram Prefilled Syringe, marketed by Rawalpindi Medical College, holds a position in the sedative-hypnotic market. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of disclosed primary indication and key trial results, which may limit market understanding and adoption.
At a glance
| Generic name | Midazolam 1 milligram Prefilled Syringe |
|---|---|
| Also known as | Dormicum |
| Sponsor | Rawalpindi Medical College |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: